Literature DB >> 3099784

Identification of UDP-galactose: lactose (lactosylceramide) alpha-4 and beta-3 galactosyltransferases in human kidney.

P Bailly, F Piller, J P Cartron, Y Leroy, B Fournet.   

Abstract

Two galactosyltransferases were identified in human kidney microsomes which both transfer galactose from UDP Gal to lactose as well as to lactosylceramide. Using a solubilized and a partially purified enzyme preparation sufficient product could be obtained for detailed structural analysis. The trisaccharide products were isolated by gel permeation chromatography and separated by preparative high performance thin layer chromatography. The anomeric configuration of the transferred galactose was determined by specific glycosidase digestion and the linkage was identified by methylation and gas-liquid-chromatography. The glycolipid products were not separated but analyzed directly, before and after alpha or beta galactosidase digestion, by methylation, hydrolysis and thin layer chromatography. Into both acceptor substrates galactose was incorporated in alpha 1-4 (30%) and beta 1-3 (70%) linkages. The alpha 1-4 galactosyltransferase is responsible for the synthesis of the Pk antigen Gal alpha 1-4 Gal beta 1-4 Glc-ceramide in human kidney. The beta 1-3 galactosyltransferase has not previously been identified.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3099784     DOI: 10.1016/s0006-291x(86)80338-2

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Adamantyl glycosphingolipids provide a new approach to the selective regulation of cellular glycosphingolipid metabolism.

Authors:  Mustafa Kamani; Murugesapillai Mylvaganam; Robert Tian; Brigitte Rigat; Beth Binnington; Clifford Lingwood
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

2.  Modification of the glycolipid-binding specificity of vero cytotoxin by polymyxin B and other cyclic amphipathic peptides.

Authors:  S Head; K Ramotar; C Lingwood
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.